MedTrace Logo

Effectiveness of Varenicline: Testing Individual Differences

NCT01228175 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2018-05-09

Study results available
· View outcomes & findings →

Summary

The study will evaluate the effectiveness of smoking cessation using Varenicline versus placebo. Effectiveness will be measured by the average number of cigarettes smoked per smoking day for up to 36 weeks.

Conditions

  • Smoking Addiction

Interventions

DRUG

Placebo

25mg look alike riboflavin tablets to match active study medication.

DRUG

Varenicline

Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • The Mind Research Network

    lead OTHER

Principal Investigators

  • Kent Hutchison, Ph.D · Director, Neurogenetics Core, The Mind Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2015-02-28
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228175 on ClinicalTrials.gov